Phenytoin Production Cost Reports

The report provides detailed analysis essential for establishing a phenytoin production plant. It encompasses all critical aspects necessary for phenytoin production, including the cost of phenytoin production, phenytoin plant cost, phenytoin production costs, and the overall phenytoin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a phenytoin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Phenytoin Market Analysis: Demand and Supply Analysis, and Sourcing

Phenytoin is a first-generation anticonvulsant used to control seizures in epilepsy. Chemically it is a hydantoin with two phenyl groups, also known as 5,5-diphenylhydantoin. It works by stabilizing nerve membranes and slowing sodium channels, which stops seizures from spreading. The drug treats epilepsy and status epilepticus, and it is on the list of essential medicines. Being an old, off-patent generic, it holds broad, steady, and global demand. First approved in 1939 as Dilantin, it has stayed a mainstay of seizure care ever since. Today the molecule is mature, cheap, and made at large scale.

Buyers are pharmaceutical and generic drug makers, along with API traders and distributors. Demand runs through tablets, capsules, oral suspensions, and injectable products based on the sodium salt. Supply is concentrated in India and China, where large antiepileptic plants run the bulk of world capacity. A phenytoin demand and supply analysis has to weigh the benzil and urea cost, the hydantoin synthesis, narrow-therapeutic-index quality needs, and steady seizure-care demand. On receipt, buyers check assay by HPLC, related substances, residual solvents, heavy metals, and water content.

Summary of the Product, Grades, and Uses

Phenytoin carries the molecular formula C15H12N2O2 and a molar mass of 252.27 g/mol under CAS 57-41-0. It is a white crystalline powder that is practically insoluble in water and better in dilute alkali. The melting point runs around 293 to 296 °C, and it is odorless with a slightly bitter taste. Being a weak acid, it forms the more soluble sodium salt, phenytoin sodium, used in injectable and many oral products. The sodium salt carries CAS 630-93-3, and it dissolves better than the free acid. In storage, it holds up well when kept cool, dry, sealed, and away from moisture.

Phenytoin reaches the market as the free acid and as the sodium salt at pharmaceutical grade. Pharmaceutical grade meets USP, European Pharmacopoeia, and BP monographs for tablets, capsules, and injections. Indian Pharmacopoeia grade serves the home market under the same tight limits. It ships as a fine crystalline powder to suit tablet, capsule, suspension, and injection blending. Buyers check assay by HPLC, related substances, individual impurities, residual solvents, heavy metals, and microbial limits against the specification.

Across the label, the roles center on epilepsy and seizure control. In chronic care, tablets and capsules control tonic-clonic and partial seizures over the long term. In emergencies, the injectable sodium salt treats status epilepticus when first-line drugs do not work. The narrow therapeutic index means levels are monitored, since the effective and toxic doses are close. Across these uses, the value comes from proven seizure control, oral and injectable forms, low cost, and a long record. Chronic epilepsy demand is broad and steady. Emergency use adds value. Such lab work covers therapeutic-level assays, method development, calibration, and analytical checks. Reference and research use is small, mostly analytical and neurological work in labs.

Main End-Uses of Phenytoin

The main use of phenytoin is as an antiepileptic drug, and this covers most demand. In practice, it goes into tablets, capsules, oral suspensions, and injectable products for seizure control. Buyers are pharmaceutical and generic formulators who run central-nervous-system lines. On these outlets, they weigh assay, related substances, content uniformity, and reliable supply. Used as a bulk active, one batch serves a large number of finished doses. On the buyer side, checks cover assay, related substances, individual impurities, and dissolution. For an antiepileptic API, the sensitive attributes are related substances, individual impurities, assay, and content uniformity.

Chronic epilepsy treatment is the largest setting. Tablets and capsules control seizures over the long term, where steady blood levels matter for a narrow-therapeutic-index drug. The large, steady epilepsy market drives most of the volume. Here the value comes from proven control, oral dosing, low cost, and compendial quality. Antiepileptics are a competitive field. Newer antiepileptic drugs compete for share. Formulators value tight quality and consistency here, since dosing is close to the toxic range.

Status epilepticus and emergency use is the second major setting. The injectable sodium salt treats prolonged seizures in hospitals when first-line drugs fail. This role keeps phenytoin important in acute neurology, even where newer agents exist, since guidelines still list it for status epilepticus that does not respond to first-line drugs. On the specification side, the key attributes are related substances, individual impurities, assay, and content uniformity. Buyers here weigh assay, related substances, consistency, and price against the grade they need. Reference and comparator use accounts for the small remainder of demand, covering therapeutic-level assays, method development, and analytical work in labs.

Phenytoin Market Risks

Phenytoin sits in the generic antiepileptic market, so its main risks are price pressure and competition rather than demand. Competition is heavy, since many makers produce the same anticonvulsant at low margins. Supply leans on India and China, so any policy shift, energy swing, or plant action there moves the whole market. Newer antiepileptic drugs compete for share, which caps growth, though phenytoin stays essential. The narrow therapeutic index raises the quality bar, since consistency is critical for safe dosing. On balance, the main pressures are price competition, supply concentration, newer drugs, and the quality bar. Underlying seizure-care demand holds up well. Most risk sits on cost and quality.

Phenytoin manufacturing carries its own risks because the synthesis and consistency both demand tight control. The hydantoin ring has to be built cleanly from benzil and urea, or related substances build up. The reaction and rearrangement have to run complete, or unreacted intermediates carry forward. Related substances and individual impurities are tightly specified, so purification has to be thorough. Because the drug has a narrow therapeutic index, assay and consistency have to be tightly held. Most rejected batches trace back to related substances, assay, and residual-solvent failures.

Phenytoin Production Process and Main Cost Drivers

The phenytoin production process runs the full value chain, from benzil and urea receipt through condensation, rearrangement, acidification, purification, salt formation, and drying.

1. By Condensation of Benzil with Urea to the Hydantoin Ring: The main inputs are benzil, urea, a base, an acid, sodium hydroxide for the salt, organic solvents & purified water.

Phenytoin production opens with receipt and QC of the benzil and urea. Benzil is reacted with urea in the presence of a base, which drives the condensation and a benzilic-acid-type rearrangement. This builds the diphenyl hydantoin ring that forms the phenytoin structure. The reaction is controlled carefully, since the rearrangement sets the yield and purity.

Next, the mixture is acidified to free phenytoin and precipitate the crude product. The crude is treated with carbon and purified, then either dried as the free acid or converted to the sodium salt with sodium hydroxide. The finished product is then crystallized, filtered, dried & milled to specification. Across the process, the critical controls are condensation completeness, rearrangement yield, related substances, and color. Assay and consistency are held tightly, since the drug has a narrow therapeutic index. QC covers assay, related substances, individual impurities, residual solvents & water content. The main levers on cost are the benzil price, condensation yield, purification recovery & salt formation.

Main Factors Affecting Phenytoin Production Cost

Phenytoin production cost is shaped mainly by benzil and the yield of the hydantoin condensation. Benzil is the largest raw material, and its price tracks its own synthesis from benzaldehyde or benzoin. Because the process runs condensation, rearrangement, and purification, yield losses shape the cost per kilogram. Urea, base, acid & solvents are steady, low-cost process inputs. Energy for the reactions, purification & drying is a real utility item. On the testing side, HPLC for related substances, residual-solvent & water tests make up most of the QC spend. On the running side, the biggest cost lines are benzil, energy, purification, and testing. Feedstock is the main driver. Yield comes next.

Unit cost also moves with condensation yield and purification recovery. A batch with heavy related substances or a poor rearrangement takes extra purification and loses yield. Because the drug has a narrow therapeutic index, tight quality control adds testing and consistency cost. Salt formation for the injectable grade adds a step and its own controls. GMP documentation, pharmacopoeia compliance & regulatory upkeep are carried as fixed overhead. The synthesis train, purification & analytical burden all carry heavy fixed overhead, so a plant running below capacity spreads that overhead over fewer kilograms and lands at a higher unit cost.

Raw Materials for Phenytoin Production Plant and its Procurement

Raw material sourcing for phenytoin centers on benzil and urea. Benzil is the primary specialty feedstock, made from benzaldehyde through benzoin and oxidation at fine-chemical plants. It ships from a limited set of makers, since benzil is a specialty intermediate. Urea, base, acid, sodium hydroxide, organic solvents & purified water complete the input streams.

The cheapest benzil is not always the cheapest route to finished phenytoin. A feed with related impurities carries side products through the condensation. Feedstock quality also shapes the related-substance profile, which is critical for a narrow-therapeutic-index drug. Taken together, benzil purity, condensation yield, rearrangement control, solvent recovery & purification recovery drive most of the variable cost per kilogram.

These sensitivities shape how a phenytoin plant buys and qualifies its inputs. Contracts specify benzil purity, related impurities, color & moisture, and every incoming lot is quarantined until QC release. Vendor qualification runs through supplier audits, review of the synthesis chain & lot-to-lot monitoring. On the incoming side, checks cover assay, related impurities, color, and moisture. Long-term agreements with two benzil suppliers help steady cost, timing, quality, and supply. Siting the plant near benzil supply and cheap energy adds real freight, feedstock & utility advantages, since benzil is the main input.

Sustainability and Regulatory Requirements

Phenytoin manufacture raises environmental concerns that center on solvent use, salt effluent & organic waste. Standard controls rely on solvent recovery, chemical effluent treatment, salt and acid neutralization & control of organic waste before discharge. Solvent use is a real concern, since the route runs organic solvents, so recovery and containment matter. Solvent recovery and energy integration cut both cost and footprint. On the sustainability side, the themes are solvent recovery, effluent treatment, salt-waste control, and energy use. Tighter environmental rules in China have already closed weaker plants and lifted compliance spending across the industry. Solvent and effluent control is the sharpest issue. Full documentation is expected.

Regulatory obligations for phenytoin follow from its use as a widely prescribed antiepileptic drug. In the US, the API sits under FDA cGMP per 21 CFR 210/211 and the USP monograph, and it is treated as a narrow-therapeutic-index drug. In Europe, an EU GMP site with a Certificate of Suitability to the European Pharmacopoeia is needed for regulated supply. ICH Q7 for active ingredients applies, along with BP, EP & USP limits on related substances. Indian grades follow their own pharmacopoeia limits. On the compliance side, the duties span cGMP, the compendial monograph, impurity limits, and effluent standards. Sites usually carry ISO 14001 and ISO 45001 certification, and batch release rests on assay, related substances, individual impurities & microbial limits.

CAPEX and OPEX for a Phenytoin Production Plant

A phenytoin plant is a synthesis and purification facility built around hydantoin chemistry. Plant investment starts with benzil and urea storage, a condensation and rearrangement reactor, and an acidification and work-up section. From there come a purification and carbon-treatment step, a salt-forming section for the sodium salt, and a crystallization, drying & milling suite. Utilities cover chilled brine, steam, purified water, solvent recovery & an effluent treatment plant. On the QC side, a laboratory block houses HPLC, related-substance testing, residual-solvent & water analysis. Civil works provide contained reactor bays, a solvent store, a drying and packing area & a controlled-access warehouse. On the capital side, the big blocks are the condensation reactor, the purification train, the effluent plant, and the drying suite. Tight quality control runs through finishing, since the drug has a narrow therapeutic index.

Phenytoin operating cost comes from the same inputs and control points that shape the process. The variable side is led by benzil, urea, sodium hydroxide & solvents, alongside energy, labor, testing, effluent treatment, packaging & freight. Cost per kilogram then comes down to condensation yield, purification recovery & salt formation. The phenytoin plant setup cost depends on capacity, synthesis and purification scale, salt-forming scope & grade range. Taken together, benzil price, condensation yield, purification recovery, energy use & compliance determine the running cost.

Plant Location and Investment Factors

A workable phenytoin site sits inside a fine-chemical cluster with benzil supply and strong effluent infrastructure. Access to trained synthesis and QC staff is essential. India's fine-chemical hubs pair benzil supply with antiepileptic chemistry and formulation capacity. China adds intermediate and API capacity with a low cost base and large chemical infrastructure. Both regions offer deep supplier networks, scale & established antiepileptic supply chains. The site also needs solvent handling, effluent treatment & a full waste system for chemical streams.

For a phenytoin plant, the main investment decision is whether to make benzil in-house or buy it and run only the final steps. Buying benzil lowers capital but leaves the biggest cost exposed to the intermediate market. Making it in-house raises CAPEX but secures supply and captures more value. Whether to make the free acid, the sodium salt, or both is the other decision, since the injectable salt needs extra steps and tighter control. Plant scale has to match steady but price-sensitive demand, so the project rests on cost leadership and reliable quality. For a maker targeting regulated markets, tight consistency & compendial quality matter most. Regulated grades pay better. Generic grades move volume.

Major Phenytoin Producing Regions

India and China are the core production regions for phenytoin today. India runs most of the world's phenytoin and phenytoin sodium API capacity, backed by large fine-chemical clusters. Regional strength rests on cheap intermediates, scale, integration, and formulation depth. China adds intermediate and API capacity with a low cost base and large chemical infrastructure. Europe holds limited but high-value capacity through specialty API makers for regulated markets. The United States relies mainly on imported API, with finished-dose work at home. Across the map, the value chain spans benzil, urea, the hydantoin condensation, and salt formation. A new plant would most likely start in an Indian or Chinese fine-chemical cluster with existing intermediate and effluent capacity.

Key Phenytoin Producers

Global Calcium

• Ranks among India's established makers of phenytoin sodium, active since the late 1970s.
• Produces phenytoin and phenytoin sodium API for regulated and export markets.
• Competes on quality, integration & wide regulatory coverage.
• Regulatory record covers US FDA, EU GMP & multi-country approvals.

Manus Aktteva Biopharma

• Operates as an Indian API supplier with phenytoin sodium in its range.
• Produces and sources phenytoin sodium for domestic and export markets.
• Competes on supply reliability, sourcing & a broad API range.
• Regulatory work covers Indian registration and export documentation.

Joshi Pharma

• Runs contract manufacture and export of APIs, including phenytoin sodium, from India.
• Produces phenytoin sodium for domestic and international markets.
• Competes on contract capacity, cost & a focused API range.
• Regulatory work covers Indian registration and export documentation.

Zhejiang Antiepileptic API Producers

• Represent the antiepileptic API capacity in China's fine-chemical clusters.
• Produce phenytoin and phenytoin sodium for domestic and export markets.
• Compete on cheap intermediates, scale & a low cost base.
• Regulatory work covers Chinese and export standards for APIs.

AdvaCare Pharma

• Manufactures phenytoin sodium tablets across facilities in China, India, and the US.
• Produces API and finished antiepileptic doses for emerging and regulated markets.
• Competes on a global footprint, cost & a broad product range.
• Regulatory work covers GMP and multi-market standards.

Aurobindo Pharma

• Manufactures a broad API and finished-dose range, with central-nervous-system capacity, from India.
• Runs synthesis and formulation of antiepileptics for regulated and emerging markets.
• Competes on scale, backward integration & wide regulatory coverage.
• Regulatory record covers US FDA, EU GMP & multi-country approvals.